JP2008512486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512486A5 JP2008512486A5 JP2007531384A JP2007531384A JP2008512486A5 JP 2008512486 A5 JP2008512486 A5 JP 2008512486A5 JP 2007531384 A JP2007531384 A JP 2007531384A JP 2007531384 A JP2007531384 A JP 2007531384A JP 2008512486 A5 JP2008512486 A5 JP 2008512486A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- inhibitor
- agonist
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 5
- 229940126033 PPAR agonist Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 3
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 3
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 3
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 239000002220 antihypertensive agent Substances 0.000 claims 3
- 230000001906 cholesterol absorption Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000009977 dual effect Effects 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 239000002461 renin inhibitor Substances 0.000 claims 3
- 229940086526 renin-inhibitors Drugs 0.000 claims 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 3
- 239000003868 thrombin inhibitor Substances 0.000 claims 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 2
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims 2
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 claims 2
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229960002478 aldosterone Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 229940127088 antihypertensive drug Drugs 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 230000000391 smoking effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 1
- NMTKJEZOWHRAQY-UHFFFAOYSA-N 8-[(6-methoxyisoquinolin-4-yl)methyl]-1-methyl-3-(2-methylpropyl)-7h-purine-2,6-dione Chemical group CC(C)CN1C(=O)N(C)C(=O)C(N2)=C1N=C2CC1=CN=CC2=CC=C(OC)C=C21 NMTKJEZOWHRAQY-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010054196 Affect lability Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000005961 cardioprotection Effects 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical group N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 206010021654 increased appetite Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940020573 plavix Drugs 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical group C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims 1
- 229960001522 ximelagatran Drugs 0.000 claims 1
- 229940051223 zetia Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60831004P | 2004-09-09 | 2004-09-09 | |
| US60957704P | 2004-09-14 | 2004-09-14 | |
| US68973805P | 2005-06-10 | 2005-06-10 | |
| PCT/US2005/032224 WO2006029349A1 (en) | 2004-09-09 | 2005-09-08 | Combination of organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008512486A JP2008512486A (ja) | 2008-04-24 |
| JP2008512486A5 true JP2008512486A5 (OSRAM) | 2008-10-23 |
Family
ID=35385557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007531384A Withdrawn JP2008512486A (ja) | 2004-09-09 | 2005-09-08 | 有機化合物の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070299047A1 (OSRAM) |
| EP (1) | EP1791600A1 (OSRAM) |
| JP (1) | JP2008512486A (OSRAM) |
| KR (1) | KR20070106677A (OSRAM) |
| AR (1) | AR050631A1 (OSRAM) |
| AU (1) | AU2005282290B2 (OSRAM) |
| BR (1) | BRPI0515185A (OSRAM) |
| CA (1) | CA2578290A1 (OSRAM) |
| GT (1) | GT200500246A (OSRAM) |
| MX (1) | MX2007002879A (OSRAM) |
| PE (1) | PE20060594A1 (OSRAM) |
| TW (1) | TW200621220A (OSRAM) |
| WO (1) | WO2006029349A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| ATE359075T1 (de) | 2002-12-20 | 2007-05-15 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
| CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| AU2013201888B2 (en) * | 2007-04-11 | 2016-02-25 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| EP3053440B1 (en) | 2007-04-11 | 2020-08-12 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| IE20070928A1 (en) * | 2007-12-21 | 2009-09-30 | Giuliani Int Ltd | Multi target ligands |
| WO2009154230A1 (ja) * | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| AU2010213093B2 (en) | 2009-02-16 | 2016-01-07 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
| CA2754901A1 (en) | 2009-03-11 | 2010-09-16 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| WO2011100659A2 (en) * | 2010-02-12 | 2011-08-18 | Kitov Pharmaceutical Ltd. | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
| CN107899012A (zh) | 2011-01-11 | 2018-04-13 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| WO2013071077A1 (en) * | 2011-11-09 | 2013-05-16 | Cornell University | The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies |
| CN104254327A (zh) | 2012-02-09 | 2014-12-31 | 诺格拉制药有限公司 | 治疗纤维化的方法 |
| JP2021534141A (ja) * | 2018-08-10 | 2021-12-09 | セルビシオ アンダルーサ デ サルー | アルコール使用障害の治療剤 |
| EP4495101A3 (en) | 2019-02-08 | 2025-04-30 | Nogra Pharma Limited | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
| IL303347A (en) | 2020-12-03 | 2023-08-01 | Delta 4 Gmbh | Clopidogrel for use in the treatment of focal segmental glomerulosclerosis (fsgs) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| FR2530247B1 (fr) * | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| AR005245A1 (es) * | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
| US6071539A (en) * | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
| US6488961B1 (en) * | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| PT1638963E (pt) * | 2003-05-20 | 2009-11-18 | Novartis Ag | Heterociclos de azoto n-acilado como ligandos de receptores activados pelo proliferador peroxissomal |
-
2005
- 2005-09-07 GT GT200500246A patent/GT200500246A/es unknown
- 2005-09-07 PE PE2005001034A patent/PE20060594A1/es not_active Application Discontinuation
- 2005-09-07 AR ARP050103737A patent/AR050631A1/es unknown
- 2005-09-08 WO PCT/US2005/032224 patent/WO2006029349A1/en not_active Ceased
- 2005-09-08 BR BRPI0515185-6A patent/BRPI0515185A/pt not_active IP Right Cessation
- 2005-09-08 CA CA002578290A patent/CA2578290A1/en not_active Abandoned
- 2005-09-08 MX MX2007002879A patent/MX2007002879A/es not_active Application Discontinuation
- 2005-09-08 US US11/574,994 patent/US20070299047A1/en not_active Abandoned
- 2005-09-08 TW TW094130818A patent/TW200621220A/zh unknown
- 2005-09-08 EP EP05796483A patent/EP1791600A1/en not_active Withdrawn
- 2005-09-08 AU AU2005282290A patent/AU2005282290B2/en not_active Expired - Fee Related
- 2005-09-08 JP JP2007531384A patent/JP2008512486A/ja not_active Withdrawn
- 2005-09-08 KR KR1020077007858A patent/KR20070106677A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008512486A5 (OSRAM) | ||
| ES2902073T3 (es) | Beta-hidroxietilaminas sustituidas con heteroarilo para uso en el tratamiento de hiperglucemia | |
| TWI337076B (en) | The use of substituted azetidinone compounds for the treatment of sitosterolemia | |
| CN101374523B (zh) | 用于治疗糖尿病的二肽基肽酶抑制剂 | |
| JP4943443B2 (ja) | コレステリルエステル輸送タンパク阻害剤としての三置換アミン化合物 | |
| US11065350B2 (en) | HSP90-targeted inflammation and infection imaging and therapy | |
| JP2016500063A5 (OSRAM) | ||
| JP2008007519A5 (OSRAM) | ||
| CN103298466B (zh) | 茶碱和非布索坦的联合治疗方法 | |
| CN111148731A (zh) | 氟苯基β-羟乙胺及其在治疗高糖血症中的用途 | |
| AR050631A1 (es) | Combinacion de compuestos organicos | |
| CN103459381A (zh) | 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸晶型及其生产方法 | |
| JP2010531361A (ja) | Ｃｂ１アタゴニストとしての置換ピペラジン | |
| US20130012548A1 (en) | Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds | |
| KR20210141622A (ko) | 과혈당증의 치료에 유용한 헤테로시클릴(페닐)메탄올 화합물 | |
| EP4470540A1 (en) | Use of heterocyclic compound | |
| DE602004006627T2 (de) | Nicotinamid-derivate, die verwendbar sind als pde4-inhibitoren | |
| JPS58225065A (ja) | ２−キノロン誘導体 | |
| JP2018507207A5 (OSRAM) | ||
| JP2025160480A (ja) | 不眠症を治療するためのレンボレキサントの使用 | |
| AU2020290094B2 (en) | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis | |
| TW202438055A (zh) | 用於處置高血糖及高血糖為特徵的疾患之取代羥甲基吡咯啶類 | |
| CN103012314A (zh) | 磺胺类化合物及其制备方法和应用 | |
| WO2025255840A1 (zh) | 治疗患者的中至重度活动性类风湿关节炎的方法 | |
| JPH0449548B2 (OSRAM) |